Iqbal J. Hussain Sells 6,000 Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA) Stock

Centessa Pharmaceuticals plc (NASDAQ:CNTA) General Counsel Iqbal J. Hussain sold 6,000 shares of the stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $16.45, for a total transaction of $98,700.00. Following the completion of the transaction, the general counsel now directly owns 105,386 shares of the company’s stock, valued at approximately $1,733,599.70. This trade represents a 5.39 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Centessa Pharmaceuticals Stock Down 2.9 %

CNTA stock opened at $16.29 on Friday. The company’s 50 day simple moving average is $16.46 and its 200-day simple moving average is $16.36. The firm has a market capitalization of $2.15 billion, a PE ratio of -10.65 and a beta of 1.54. Centessa Pharmaceuticals plc has a 12 month low of $7.75 and a 12 month high of $19.09. The company has a debt-to-equity ratio of 0.15, a current ratio of 21.52 and a quick ratio of 21.52.

Analyst Ratings Changes

A number of research analysts have issued reports on the stock. Guggenheim reaffirmed a “buy” rating on shares of Centessa Pharmaceuticals in a report on Monday, February 10th. TD Cowen assumed coverage on shares of Centessa Pharmaceuticals in a report on Tuesday, January 7th. They issued a “buy” rating for the company. Finally, Morgan Stanley reaffirmed an “overweight” rating and issued a $27.00 target price on shares of Centessa Pharmaceuticals in a report on Friday, March 7th. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $26.00.

Institutional Trading of Centessa Pharmaceuticals

Several large investors have recently modified their holdings of CNTA. Price T Rowe Associates Inc. MD boosted its position in Centessa Pharmaceuticals by 14.6% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 5,364,392 shares of the company’s stock worth $89,854,000 after acquiring an additional 685,371 shares during the last quarter. Adage Capital Partners GP L.L.C. boosted its holdings in shares of Centessa Pharmaceuticals by 22.0% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 5,119,027 shares of the company’s stock valued at $85,744,000 after purchasing an additional 924,027 shares during the last quarter. Janus Henderson Group PLC boosted its holdings in shares of Centessa Pharmaceuticals by 279.2% in the 4th quarter. Janus Henderson Group PLC now owns 4,909,487 shares of the company’s stock valued at $82,218,000 after purchasing an additional 3,614,623 shares during the last quarter. Farallon Capital Management LLC boosted its holdings in shares of Centessa Pharmaceuticals by 24.3% in the 4th quarter. Farallon Capital Management LLC now owns 3,498,709 shares of the company’s stock valued at $58,603,000 after purchasing an additional 684,391 shares during the last quarter. Finally, Point72 Asset Management L.P. boosted its holdings in shares of Centessa Pharmaceuticals by 26.2% in the 4th quarter. Point72 Asset Management L.P. now owns 3,426,599 shares of the company’s stock valued at $57,396,000 after purchasing an additional 710,936 shares during the last quarter. 82.01% of the stock is currently owned by institutional investors and hedge funds.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.